Group using CBDCA-E regime often happen more hematological and non-hematological toxicities and should take more support treated measures than group using AVI regime. Conclusion: Management of combinative chemotherapy of the first step by AVI regime for SCLC and then using CBDCA-E regime of the second step in case of failure to be effective, particularly in patients with LD-SCLC.